How do I choose a MAT program that offers Suboxone in Ontario?

Quick answer: what this article will help you do

This article gives an evidence‑backed checklist you can use to compare outpatient medication‑assisted treatment (MAT) programs that prescribe Suboxone (buprenorphine/naloxone) in Ontario, explains where Suboxone fits among the main MAT options, describes intake assessments you may encounter, and lists practical verification questions to ask clinics and pharmacies. For selection factors to use when comparing programs, see the Treatment Association guidance on choosing an addiction treatment program (Treatment Association guidance on choosing a program).

Checklist: concrete things to compare when a program offers Suboxone

The Treatment Association lists core factors to guide choosing an addiction treatment program. Use the points below as direct questions to verify with any clinic that says it prescribes Suboxone (Treatment Association guidance):

• Which substance and use history do you treat? Ask whether the program treats opioid use disorder with buprenorphine/Suboxone and whether your pattern and duration of opioid use fit their intake criteria. The Treatment Association names the substance used and how long it’s been used as central selection factors (Treatment Association guidance).
• Do you screen for and manage co‑occurring mental‑health conditions? Confirm whether the program performs mental‑health screening and whether it provides or arranges psychiatry or counselling referrals; co‑occurring conditions are a named factor in the Treatment Association checklist (Treatment Association guidance).
• What access options do you offer and how quickly can I start? Ask how new intakes are scheduled and whether there are rapid or same‑day intake options for initiating medication. The Treatment Association highlights practical access as part of choosing a suitable program (Treatment Association guidance).
• What are coverage, cost, and pharmacy arrangements? Ask which MAT medications your plan or local public coverage will reimburse and which pharmacies the program works with for dispensing Suboxone. Insurance, coverage and pharmacy logistics are practical selection questions to verify directly with the clinic (Treatment Association guidance).
• How does past treatment history and family/work obligations affect care? Tell the clinic about earlier treatment attempts and scheduling needs; the Treatment Association lists prior treatment history and family obligations as factors that should shape your choice (Treatment Association guidance).

Tip: treat each answer as verifiable: ask for the clinic’s intake policy, their written criteria for opioid agonist therapy (if any), and for the names of pharmacies they coordinate with so you can call and confirm dispensing availability. If insurance or public coverage is unclear, ask the clinic to provide written or emailed confirmation of expected coverage for the medication options they recommend — coverage is an explicit selection factor in the Treatment Association guidance (Treatment Association guidance).

Where Suboxone fits among MAT medications

Clinical summaries and public guidance list the primary MAT medications and named buprenorphine formulations used in programs. For example, Birchwood Health names Suboxone (buprenorphine/naloxone), methadone, and extended‑release naltrexone (Vivitrol) as the three primary MAT medications (Birchwood’s MAT guide), and the CDC’s MAT overview specifically lists sublingual film products (for example, Cassipa, Suboxone) among buprenorphine formulations (CDC overview of MAT formulations).

What to ask a clinic about medication options:

• Which MAT medicines do you prescribe (buprenorphine/Suboxone, methadone, naltrexone)?
• If you prescribe buprenorphine, which formulation(s) do you use (e.g., sublingual film such as Suboxone)? Use the CDC’s formulation list to match the clinic’s answer (CDC overview of MAT formulations).
• How do you decide which medication is right for a given patient (ask for their clinical criteria)?

Ask the clinic to name the exact marketed formulation they intend to prescribe so you can confirm whether that product is stocked locally. The CDC list of buprenorphine products will help you match the clinic’s term to a marketed product when you call pharmacies (CDC overview of MAT formulations).

What to expect at intake: assessments, early steps, and integrated care

Intake processes vary by program and jurisdiction. Some program materials document specific steps used in that program; use those examples to form verification questions you can ask your clinic.

For example, UCSF MAT materials state that after receiving an appropriate referral to their MAT program, patients complete an ASAM assessment as part of that program’s intake process. That excerpt is a program‑level description and does not mean every program uses ASAM; ask any clinic whether they use an ASAM assessment or another standardized tool during intake (UCSF MAT materials (ASAM assessment mention)).

Suggested verification questions about intake and early clinical steps:

• Do you use a standardized assessment (for example, ASAM) at intake? If so, can you share which assessment and what to expect?
• What happens after the assessment — will I meet a nurse, clinician, or prescriber, and on what timeline?
• What medical checks and monitoring will occur before and after starting medication (for example, initial urine screening, vital signs, or follow‑up frequency)? Ask the clinic to describe their monitoring policy in plain terms.

Use program examples such as the UCSF excerpt to inform the question you ask, and record the clinic’s written intake steps before you commit. The UCSF example shows programs sometimes publish intake tools and local pharmacy arrangements; request those documents or a written summary so you know the clinic’s expected follow‑up timeline and pharmacy partner before starting (UCSF MAT materials (ASAM assessment mention)).

How to verify local logistics (pharmacies, dispensing, and clinic details)

Pharmacy arrangements and dispensing practices can be program‑specific. Some program materials explicitly name a dispensing pharmacy in their example materials, which shows that clinics sometimes document a local pharmacy partner — use that as a model for verification with any clinic you contact. The UCSF program materials include an example that names a pharmacy used by that program, illustrating why you should confirm the exact pharmacy arrangement for the program you choose (UCSF MAT materials (pharmacy example)).

As a local, practical example of program materials you can review before calling a clinic, see the Suboxone Care: Cut Cravings and Start Fresh in guide.

Key questions to ask clinics and pharmacies before you start:

• Which buprenorphine/Suboxone formulation do you prescribe (sublingual film, tablets, or other)? Refer to the CDC formulation list to match the clinic’s term to a marketed product (CDC overview of MAT formulations).
• Which local pharmacies do you recommend or coordinate with for dispensing Suboxone, and will you contact the pharmacy on my behalf?
• If a pharmacy is named, call that pharmacy to confirm they dispense the specific Suboxone formulation and ask about any identification or pick‑up procedures they require.
• What coverage or cost can I expect under my public or private plan for the medication options the clinic prescribes? The Treatment Association lists coverage and insurance as a practical selection factor to verify (Treatment Association guidance).

Recording the clinic and pharmacy names, the medication formulation, and any billing information in writing before beginning treatment reduces surprises and gives you concrete follow‑up steps if a pharmacy cannot fill the prescription.

FAQ

Will I usually be offered counselling or behavioural treatment along with Suboxone?

Many program planning documents and guidance note that behavioural treatment is available in conjunction with MAT. For example, the SAMHSA/NY Courts materials state that behavioural treatment is available alongside MAT and list Buprenorphine/Suboxone among the medications used; ask any clinic how counselling or mental‑health referral is integrated into your individual care plan (SAMHSA / NY Courts PDF on MAT and behavioural care).

What other medications are commonly used in MAT besides Suboxone?

Clinical overviews list methadone and extended‑release naltrexone (Vivitrol) alongside buprenorphine/Suboxone as primary MAT medications to discuss with a provider. See the Birchwood MAT guide for a concise listing of Suboxone, methadone and Vivitrol as the main medication options to consider and compare (Birchwood’s MAT guide).

What intake assessments should I expect when starting a MAT program that prescribes Suboxone?

Expect that programs will use some form of clinical assessment during intake, but tools vary by program. The UCSF materials describe completing an ASAM assessment after referral to that MAT program, which is an example of a standardized intake evaluation used in some settings; ask your clinic which assessment they use and what it covers (UCSF MAT materials (ASAM assessment mention)).

How can I verify which pharmacy will fill my Suboxone prescription?

Because dispensing arrangements are program‑specific, ask the clinic which pharmacies they work with and then call the named pharmacy to confirm they dispense the exact formulation the clinic prescribes. The UCSF program example that names a pharmacy demonstrates this is sometimes specified at the program level, so verify the pharmacy details directly with both the clinic and the pharmacy before you begin treatment (UCSF MAT materials (pharmacy example)).

Talk with Road To Recovery

Contact Road To Recovery to ask about the next step and confirm which options fit your needs.